Pulse Biosciences Inc
$ 24.28
-1.58%
02 Jun - close price
- Market Cap 1,707,404,000 USD
- Current Price $ 24.28
- High / Low $ 24.75 / 23.60
- Stock P/E N/A
- Book Value 1.19
- EPS -1.10
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.45 %
- ROE -0.81 %
- 52 Week High 27.98
- 52 Week Low 12.56
About
Pulse Biosciences, Inc. is a bioelectrical medicine startup. The company is headquartered in Hayward, California.
Analyst Target Price
$30.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-04 | 2026-02-19 | 2025-11-05 | 2025-08-12 | 2025-05-08 | 2025-03-27 | 2024-10-30 | 2024-08-12 | 2024-05-07 | 2024-03-28 | 2023-11-13 | 2023-08-10 |
| Reported EPS | -0.2414 | -0.18 | -0.29 | -0.28 | -0.2502 | -0.3124 | -0.2076 | -0.1991 | -0.1837 | -0.2167 | -0.19 | -0.22 |
| Estimated EPS | -0.22 | -0.21 | -0.31 | -0.26 | None | -0.24 | -0.24 | -0.2 | -0.24 | -0.24 | -0.22 | -0.22 |
| Surprise | -0.0214 | 0.03 | 0.02 | -0.02 | 0 | -0.0724 | 0.0324 | 0.0009 | 0.0563 | 0.0233 | 0.03 | 0 |
| Surprise Percentage | -9.7273% | 14.2857% | 6.4516% | -7.6923% | None% | -30.1667% | 13.5% | 0.45% | 23.4583% | 9.7083% | 13.6364% | 0% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PLSE
2026-05-29 10:09:16
Pulse Biosciences Inc (PLSE) shows a "Strong Buy" technical sentiment based on Intellectia's analysis, with 7 out of 10 indicators flashing buy signals. The stock is trading above its 60-day and 200-day moving averages, and key indicators like MACD suggest a positive outlook, while RSI indicates a neutral condition. Support is identified at $23.187 and resistance at $27.917.
2026-05-29 10:09:16
This article provides a financial analysis of Pulse Biosciences Inc (PLSE), detailing its revenue breakdown, profitability margins, and a comparison with competitors. The company's revenue is primarily driven by Systems, accounting for 78.9% of total sales, while its gross margin stands at 7.73%, with negative operating and net margins. PLSE, with a market capitalization of $1.71B, is benchmarked against BWAY and PRCT, highlighting significant differences in gross margins.
2026-05-28 18:09:16
Pulse Biosciences is poised to transform thyroid and cardiac care with its nanosecond pulse field ablation (PFA) technology, which is achieving early commercial success in benign thyroid nodule ablation and advancing through clinical trials for atrial fibrillation. Analysts project significant revenue growth of over 600% annually for the next three years, though profitability is not expected within that timeframe. Despite the promising outlook, the company faces risks including slow adoption, high operating expenses, and competitive pressures, with analysts setting a consensus price target of $22.0.
2026-05-28 03:09:15
Pulse Biosciences, Inc. (Nasdaq: PLSE) announced its participation in the Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, FL. Management is scheduled to present on Wednesday, June 10, at 10:00 am ET. A webcast of the fireside chat will be available on the company’s investor website.
2026-05-27 19:38:56
Pulse Biosciences, Inc. announced its participation in the Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, FL. The company's management is scheduled to present on Wednesday, June 10, at 10:00 AM ET. Pulse Biosciences develops nPulse™ technology for non-thermal cell clearance while sparing adjacent non-cellular tissue, and is pursuing its use in treating atrial fibrillation and other markets.
2026-05-21 11:12:32
Pulse Biosciences (PLSE) has experienced a significant surge in its share price, with a 34.22% increase over the past week and a 91.26% year-to-date return, bringing its market value to approximately US$1.70 billion. Despite this momentum, Simply Wall St's fair value narrative suggests the stock is overvalued by 16.4% at $25.61 compared to a fair value of $22. The company's advancing clinical programs for cardiac surgical tools point to future growth, but risks related to clinical data and profitability remain.
